[Skip to Content]
[Skip to Content Landing]
Article
November 20, 1987

Colestipol-Niacin Therapy and Coronary Atherosclerosis

Author Affiliations

New York Hospital—Cornell Medical Center

New York Hospital—Cornell Medical Center

JAMA. 1987;258(19):2694. doi:10.1001/jama.1987.03400190076017
Abstract

To the Editor.—  In the article entitled "Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts," Blankenhorn et al1 presented exciting data concerning the possible stabilization of and improvement in coronary lesions in patients with a previous history of coronary bypass grafting who were treated with diet and cholesterol-reducing drugs.According to the design of the study, in a prerandomization screening phase, patients who could not tolerate the medications or who failed to achieve a significant lowering of cholesterol level (≥15%) were excluded from the randomized, placebo-controlled study. The number of excluded patients was not given.I believe it is important to note that the patients who took the drugs for two years were very unusual in being motivated to tolerate the high incidence of side effects that were noted. I also believe that they were more likely to follow a strict diet. I

×